We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Guardant Health (GH) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Guardant Health (GH - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Guardant Health is a member of our Medical group, which includes 887 different companies and currently sits at #1 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. GH is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for GH's full-year earnings has moved 30.24% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that GH has returned about 94.12% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of 3.50% on a year-to-date basis. This shows that Guardant Health is outperforming its peers so far this year.
Breaking things down more, GH is a member of the Medical - Biomedical and Genetics industry, which includes 376 individual companies and currently sits at #56 in the Zacks Industry Rank. Stocks in this group have gained about 1.78% so far this year, so GH is performing better this group in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track GH. The stock will be looking to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Guardant Health (GH) Outperforming Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Guardant Health (GH - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Guardant Health is a member of our Medical group, which includes 887 different companies and currently sits at #1 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. GH is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for GH's full-year earnings has moved 30.24% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that GH has returned about 94.12% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of 3.50% on a year-to-date basis. This shows that Guardant Health is outperforming its peers so far this year.
Breaking things down more, GH is a member of the Medical - Biomedical and Genetics industry, which includes 376 individual companies and currently sits at #56 in the Zacks Industry Rank. Stocks in this group have gained about 1.78% so far this year, so GH is performing better this group in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track GH. The stock will be looking to continue its solid performance.